Tucatinib
- Generic Name
- Tucatinib
- Brand Names
- Tukysa
- Drug Type
- Small Molecule
- Chemical Formula
- C26H24N8O2
- CAS Number
- 937263-43-9
- Unique Ingredient Identifier
- 234248D0HH
- Background
Tucatinib is a kinase inhibitor drug used with trastuzumab and capecitabine in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.
- Indication
本品与曲妥珠单抗和卡培他滨联用治疗人类表皮生长因子受体2(HER2)阳性且已出现转移(如脑转移)或无法进行乳房切除术的乳腺癌成人患者，患者应接受过一种或多种抗HER2乳腺癌药物治疗。
- Associated Conditions
- Breast Cancer, Unresectable Breast Cancer, Wild-type RAS Metastatic Colorectal Cancer, Unresectable RAS Wild Type Colorectal Cancer
Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 42
- Registration Number
- NCT03054363
- Locations
- 🇺🇸
University of Texas Health Science Center San Antonio, San Antonio, Texas, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
🇺🇸University of Colorado Denver, Aurora, Colorado, United States
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
- Conditions
- Metastatic Colorectal Adenocarcinoma
- Interventions
- First Posted Date
- 2017-02-06
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 117
- Registration Number
- NCT03043313
- Locations
- 🇺🇸
Texas Oncology - Beaumont, Beaumont, Texas, United States
🇺🇸Lombardi Cancer Center / Georgetown University Medical Center, Washington, District of Columbia, United States
🇪🇸Hospital General Universitario Gregorio Maranon, Madrid, Other, Spain
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
- Conditions
- HER2-expressing Cancers
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 279
- Registration Number
- NCT02892123
- Locations
- 🇺🇸
Hoag Family Cancer Institute, Newport Beach, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Conditions
- Lymphoma, Non-HodgkinMultiple MyelomaAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2016-02-26
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- American Society of Clinical Oncology
- Target Recruit Count
- 4200
- Registration Number
- NCT02693535
- Locations
- 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Cancer Treatment Centers of America-Phoenix, Phoenix, Arizona, United States
🇺🇸Sutter Auburn, Auburn, California, United States
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
- Conditions
- HER2 Positive Breast Cancer
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 612
- Registration Number
- NCT02614794
- Locations
- 🇺🇸
Carle Cancer Center, Urbana, Illinois, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸Paris Regional Medical Center / US Oncology, Paris, Texas, United States
A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer
- Conditions
- HER2 Positive Metastatic Breast Cancers
- Interventions
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02025192
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Northwest Medical Specialties, Tacoma, Washington, United States
🇺🇸Providence Cancer Center, Portland, Oregon, United States
A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
- Conditions
- HER2 Positive Breast Cancers
- Interventions
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT01983501
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇨🇦Hospital de la Cite-de-la-Sante, Laval, Quebec, Canada
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Conditions
- HER2-negative Breast CancerHormone Receptor Positive TumorAngiosarcomaTNBC - Triple-Negative Breast CancerBreast NeoplasmsBreast TumorsHER2-positive Breast CancerHormone Receptor Negative TumorBreast CancerEarly-stage Breast Cancer
- Interventions
- Drug: Standard TherapyDrug: AMG 386 with or without TrastuzumabDrug: AMG 479 (Ganitumab) plus MetforminDrug: SYD985 ([vic-]trastuzumab duocarmazine)Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumabDrug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumabDrug: Datopotamab deruxtecan + DurvalumabDrug: Rilvegostomig + TDXdDrug: AMG 386 and Trastuzumab
- First Posted Date
- 2010-01-05
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 5000
- Registration Number
- NCT01042379
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Texas, Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of Kansas, Westwood, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.